PTPN13/PTPL1 Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 1 mg/ml

PTPN13/PTPL1 Antibody Blocking Peptide Summary

• Specificity: This peptide is specific for NB100-56140 only.
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: PTPN13

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NB100-56140. For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: Peptide dissolved in dH20. Contains no BSA.
• Preservative: No Preservative
• Concentration: 1 mg/ml

Alternate Names for PTPN13/PTPL1 Antibody Blocking Peptide

• EAP-1
• FAP-1
• hPTPE1
• PNP1
• protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associatedphosphatase)
• protein-tyrosine phosphatase 1, Fas-associated
• PTP1E
• PTP1EDKFZp686J1497
• PTP-BAS
• PTP-BASEC 3.1.3.48
• PTP-BL
• PTP-E1
• PTPL1
• PTPL1nonreceptor type 13
• PTPLE
• PTPN13
• tyrosine-protein phosphatase non-receptor type 13

Background

FAP-1 (also known as Fas-associated phosphatase-1, PTPN13, PTP-BAS, hPTPIE, and PTPL1) is a member of the protein tyrosine phosphatase (PTP) family (reviewed in Meinhold-Heerlein et al, 2001; Savaskan et al, 2005; Foehr et al, 2005; and Ivanov et al, 2006). PTPs are enzymes that catalyze the removal of a phosphate group attached to a tyrosine residue. Most intracellular signaling involves reversible phosphorylation events; therefore, PTPs are central to the dynamic regulation of signaling cascades that underlie cell functions. For example, PTPs play key roles in regulating cell growth, differentiation, proliferation, inflammation, and oncogenic transformation. PTPs are emerging as a promising class of signaling targets for diseases such as cancer, neurodegeneration, diabetes, and inflammation. A key challenge is to identify specific PTPs that are invovled in a disease process and develop therapeutics to modulate the PTP. FAP-1 phosphatase is thought to be important in the Fas signaling pathway. FAP-1 binds to the cytosolic tail of the Fas receptor (Apo1, CD95) and inhibits Fas-induced apoptosis. Increased FAP-1 protein levels in some tumor cell lines and tumor tissues correlates with resistance to Fas-mediated apoptosis. In general, FAP-1 expression has been found to be highest in cell lines and tissues that are relatively resistant to Fas-mediated apoptosis. Gene transfer-mediated elevations in FAP-1 partially abolished Fas-induced apoptosis in a T cell line which is consistent with an inhibitory effect of FAP-1 on Fas signal transductions. Additionally, FAP-1 expression correlates with Fas resistant in ovarian cancer cell lines and FAP-1 is commonly expression in ovarian cancers. Human Fas has a putative consensus tyrosine phosphorylation site (Tyrosine 275) suggesting that Fas surface expression or signaling may be regulated by phosphorylation. FAP-1 has been shown to directly bind to Fas and may dephosphorylate Fas as part of the down regulation of the apoptotic pathway. It is thought that development of therapeutics to inhibit FAP-1 may increase the ability of tumor cells with upregulated FAP-1 to undergo apoptosis. FAP-1 is a large approx. 270 kDa protein. Multiple alternatively spliced FAP-1 transcript variants which encode distinct proteins have been reported, including shorter forms. Please see Application Notes section for additional details on FAP-1 isoforms.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: PTPN13